Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other ...

Chances are good that you've heard a lot of ways to avoid, treat or cure COVID-19 (coronavirus disease 2019). If what you heard doesn't mention a COVID-19 vaccine or COVID-19 medicine from your ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd ...

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.

Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...